Experienced in Primary Lymphoma of the Brain

Dr. Tianhong M. Li

Hematology Oncology | Hematology | Oncology
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Primary Lymphoma of the Brain
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tianhong Li is a Hematologist Oncology specialist and a Hematologist in Merced, California. Dr. Li is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Tissue Biopsy, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 76 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
University Of California Davis Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

REGENTS OF THE UNIV OF CA
3850 G St, Merced, CA 95340

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan Hydrochloride
Study Phase: Phase 1
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
Treatment of Immune Related Adverse Events With CD24Fc (TIRAEC)
Treatment of Immune Related Adverse Events With CD24Fc (TIRAEC)
Enrollment Status: Terminated
Publish Date: August 02, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Unknown
Publish Date: March 08, 2023
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
Enrollment Status: Unknown
Publish Date: February 01, 2021
Intervention Type: Drug
Study Drug: Pyrotinib
Study Phase: Phase 1
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

76 Total Publications

Neuromuscular complications associated with cancer immunotherapy.
Neuromuscular complications associated with cancer immunotherapy.
Journal: Journal of the National Cancer Center
Published: January 29, 2025
Similar Doctors
Distinguished in Primary Lymphoma of the Brain
Dr. Haifaa Abdulhaq
Hematology Oncology | Hematology | Oncology
Distinguished in Primary Lymphoma of the Brain
Dr. Haifaa Abdulhaq
Hematology Oncology | Hematology | Oncology

Community Health Partners

785 N Medical Ctr Dr W, Suite 203, 
Clovis, CA 
 (56.2 miles away)
559-387-1900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Haifaa Abdulhaq is a Hematologist Oncology specialist and a Hematologist in Clovis, California. Dr. Abdulhaq is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

Advanced in Primary Lymphoma of the Brain
Dr. Paul R. Kaesberg
Hematology Oncology | Oncology | Hematology
Advanced in Primary Lymphoma of the Brain
Dr. Paul R. Kaesberg
Hematology Oncology | Oncology | Hematology

Regents Of The Univ Of Ca

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-384-6528
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Kaesberg is a Hematologist Oncology specialist and an Oncologist in Merced, California. Dr. Kaesberg has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Advanced in Primary Lymphoma of the Brain
Dr. Aaron S. Rosenberg
Hematology Oncology | Hematology | Oncology
Advanced in Primary Lymphoma of the Brain
Dr. Aaron S. Rosenberg
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-384-6528
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aaron Rosenberg is a Hematologist Oncology specialist and a Hematologist in Merced, California. Dr. Rosenberg is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile